Brokerages expect that Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) will announce $0.38 earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Maravai LifeSciences’ earnings, with estimates ranging from $0.35 to $0.43. Maravai LifeSciences reported earnings of $0.13 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 192.3%. The firm is expected to announce its next earnings results on Tuesday, March 1st.
According to Zacks, analysts expect that Maravai LifeSciences will report full-year earnings of $1.51 per share for the current financial year, with EPS estimates ranging from $1.49 to $1.52. For the next fiscal year, analysts forecast that the business will report earnings of $1.54 per share, with EPS estimates ranging from $1.46 to $1.64. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Maravai LifeSciences.
Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings results on Wednesday, November 10th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.09. The company had revenue of $204.81 million for the quarter, compared to the consensus estimate of $199.68 million. Maravai LifeSciences had a return on equity of 109.36% and a net margin of 22.69%.
MRVI stock opened at $30.33 on Friday. The company’s 50-day simple moving average is $38.80 and its 200-day simple moving average is $43.85. The company has a quick ratio of 5.52, a current ratio of 6.01 and a debt-to-equity ratio of 1.28. Maravai LifeSciences has a 52-week low of $26.81 and a 52-week high of $63.55. The firm has a market cap of $7.82 billion, a P/E ratio of 29.16 and a beta of 0.04.
A number of institutional investors have recently modified their holdings of the stock. Spire Wealth Management acquired a new stake in Maravai LifeSciences in the 4th quarter valued at about $71,000. Diversified Trust Co raised its holdings in Maravai LifeSciences by 11.2% in the 4th quarter. Diversified Trust Co now owns 14,875 shares of the company’s stock valued at $623,000 after acquiring an additional 1,500 shares during the last quarter. Hudson Bay Capital Management LP acquired a new stake in Maravai LifeSciences in the 3rd quarter valued at about $4,417,000. Jefferies Group LLC raised its holdings in Maravai LifeSciences by 137.5% in the 3rd quarter. Jefferies Group LLC now owns 47,974 shares of the company’s stock valued at $2,355,000 after acquiring an additional 27,774 shares during the last quarter. Finally, UBS Asset Management Americas Inc. raised its holdings in Maravai LifeSciences by 16.8% in the 3rd quarter. UBS Asset Management Americas Inc. now owns 4,133,186 shares of the company’s stock valued at $202,857,000 after acquiring an additional 594,447 shares during the last quarter. 50.31% of the stock is currently owned by hedge funds and other institutional investors.
Maravai LifeSciences Company Profile
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.